Summit 2013 Sessions

FOR PROFESSIONALS

FRIDAY > SCIENTIFIC SESSIONS

Welcome and Introduction

• Daniel M. Rose, MD, CEO and Chairman of the Board, Pulmonary Fibrosis Foundation | VIEW SLIDES | WATCH WEBINAR

Opening Session Keynote Address

• Cystic Fibrosis Therapeutic Development: A Game Changer,  Robert J. Beall, PhD, President and CEO and Chairman of the Board, Cystic Fibrosis Foundation | VIEW SLIDES | WATCH WEBINAR

Lung Injury and Repair

Leaders: Gregory P. Cosgrove, MD; Martin Kolb, MD, PhD; Patricia J. Sime, MD

• Introduction: Lung Injury and Repair, Gregory P. Cosgrove, MD | VIEW SLIDES | WATCH WEBINAR

• Targeting Matrix: Opportunities for Therapy, Patricia J. Sime, MD | VIEW SLIDES | WATCH WEBINAR

• Role of Alveolar Epithelium in Pulmonary Fibrosis: Innocent Bystander or Active Participant?, Zea Borok, MD | VIEW SLIDES | WATCH WEBINAR

• IPF Fibroblasts and Their Cell-of-Origin, Craig Henke, MD | VIEW SLIDES | WATCH WEBINAR

• Cell Based Therapy to Correct the Tissue Milleu in IPF [Amniotic Fluid Stem Cell Therapy for the Treatment of Lung Disease], Orquidea Garcia, PhD for David Warburton, MD | VIEW SLIDES | WATCH WEBINAR

Special Luncheon Speaker

• When Drug Research is Personal: The Importance of Patient Advocacy in Drug Development and Innovation, John F. Crowley, JD, MBA, Chairman and CEO, Amicus Therapeutics | VIEW SLIDES | WATCH WEBINAR

Personalized Medicine: Genetics and Biomarkers

Leader: Fernando J. Martinez, MD, MS

• Introduction: Genetics and Biomarkers, Fernando J. Martinez

• Genetic Markers: Impact on Outcome and Patient Management, Christine Kim Garcia, MD, PhD | VIEW SLIDES | WATCH WEBINAR

• Genome-wide Approach to Personalized Survival in IPF, Imre Noth, MD | VIEW SLIDES | WATCH WEBINAR

• Implementing Protein-based Biomarkers in IPF: Challenges and Future Directions, Ivan O. Rosas, MD | VIEW SLIDES | WATCH WEBINAR

• Implications of Genetic Data, Janet Talbert, MS, CGC | VIEW SLIDES | WATCH WEBINAR

Drug Development in IPF (sessions not included in CME)

Leaders: A. Bruce Montgomery, MD; Dean Sheppard, MD

• Introduction: Comparison of Regulatory Agencies and the Approval Process, A. Bruce Montgomery, MD | VIEW SLIDES | WATCH WEBINAR

• Promising Therapeutic Targets, Dean Sheppard, MD | VIEW SLIDES | WATCH WEBINAR

• Challenges of IPF Drug Development, Tom O'Riordan, MD | VIEW SLIDES | WATCH WEBINAR

SATURDAY  > CLINICAL SESSIONS

Leaders: Kevin R. Flaherty, MD, MS; Marvin I. Schwarz, MD; Jeffrey James Swigris, DO, MS; Leslie C. Watters, MD

• Making an Accurate Diagnosis: How to Use the IPF Consensus Guidelines, Fernando J. Martinez, MD, MS | VIEW SLIDES | WATCH WEBINAR

• Sleep Apnea and IPF: Coincidence or Causation?, David Lederer, MD, MS | VIEW SLIDES | WATCH WEBINAR

• Pulmonary Hypertension in PF: To Test? To Treat?, Steven M. Kawut, MD, MS | VIEW SLIDES | WATCH WEBINAR

• GERD and Microaspiration in PF: Fundoplication for Everyone?, Joyce Lee, MD | VIEW SLIDES | WATCH WEBINAR

• Case Presentations with Master Clinicians | VIEW SLIDES | WATCH WEBINAR

• Talking with PF Patients: Truth-telling while Maintaining Hope, Jeffrey James Swigris, DO, MS | VIEW SLIDES | WATCH WEBINAR

• Patient and Pulmonologist Journey with IPF: A Breathtaking Experience, Craig S. Conoscenti, MD | VIEW SLIDES | WATCH WEBINAR

Existing and New Treatment Options: A Global Perspective

• Non-Pharmacologic Treatment Options, Christopher J. Ryerson, MD | VIEW SLIDES | WATCH WEBINAR

Pirfenidone Treatment of IPF in the European Union, Carlo Vancheri, MD | VIEW SLIDES | WATCH WEBINAR

• Future of Therapies and Clinical Trials, Kevin K. Brown, MD | VIEW SLIDES | WATCH WEBINAR

Clinical Trial Updates (sessions not included in CME)

Leader: Kevin K. Brown, MD

• STX-100 (anti-αvβ6 mAb) in Patients with Idiopathic Pulmonary Fibrosis, Brad Maroni, MD, Biogen Idec | VIEW SLIDES | WATCH WEBINAR

• Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist (BMS 986020) in Idiopathic Pulmonary Fibrosis, Claudio Pasquinelli, MD, PhD, Bristol-Myers Squibb | VIEW SLIDES | WATCH WEBINAR

• A Phase II Clinical Trial Evaluating JNK Inhibitor Tanzisertib (CC-930) in IPF, Gregory Ferguson, PhD, Celgene | VIEW SLIDES | WATCH WEBINAR

• Treatment of Idiopathic Pulmonary Fibrosis with Anti-CTGF Monoclonal Antibody FG-3019: Interim Results of Phase 2 Clinical Trial,  John Stauffer, MD, FibroGen | VIEW SLIDES | WATCH WEBINAR

• Overview of Lebrikizumab Program in Idiopathic Pulmonary Fibrosis (RIFF Study), Ari Gershman, DO, Genentech | VIEW SLIDES | WATCH WEBINAR

• Protocol GS-US-322-0207: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER),  Thomas O’Riordan, MD, Gilead | VIEW SLIDES | WATCH WEBINAR

• ImmuneWorks Lead Asset: IW001, David Wilkes, MD, ImmuneWorks | VIEW SLIDES | WATCH WEBINAR

• Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) – the ASCEND Trial, Jonathan Leff, MD, InterMune | VIEW SLIDES | WATCH WEBINAR

• An Adaptive, 2‑Staged, Randomized, Placebo‑controlled Study to Evaluate the Tolerability, Safety, and Efficacy of PRM‑151 in Patients with Idiopathic Pulmonary Fibrosis (IPF), Elizabeth Trehu, MD, Promedior | VIEW SLIDES | WATCH WEBINAR

Advocacy

Effective Advocacy for Pulmonary Fibrosis, Brain Baird, MS, PhD | VIEW SLIDES | WATCH WEBINAR

HOME  |  PULMONARY FIBROSIS FOUNDATION  |  FAQs  |  LEGAL TERMS AND CONDITIONS | PRIVACY POLICY  |   CONTACT US